DaVita (NYSE:DVA) Stock Rating Upgraded by Wall Street Zen

DaVita (NYSE:DVA) was upgraded by Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued on Saturday.

Several other research analysts have also issued reports on DVA. Barclays cut their target price on shares of DaVita from $169.00 to $160.00 and set an “equal weight” rating for the company in a research report on Thursday, August 7th. Bank of America cut their target price on shares of DaVita from $145.00 to $140.00 and set an “underperform” rating for the company in a research report on Wednesday. Finally, Truist Financial set a $148.00 price target on shares of DaVita in a research report on Friday, August 8th. Three equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Reduce” and an average target price of $158.00.

DaVita Trading Down 0.1%

Shares of DVA stock opened at $133.08 on Friday. The company’s fifty day simple moving average is $138.45 and its two-hundred day simple moving average is $141.54. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.39 and a quick ratio of 1.34. DaVita has a 1 year low of $126.07 and a 1 year high of $179.60. The stock has a market capitalization of $9.52 billion, a price-to-earnings ratio of 13.09, a PEG ratio of 0.95 and a beta of 1.13.

DaVita (NYSE:DVA) last released its quarterly earnings results on Tuesday, August 5th. The company reported $2.95 earnings per share for the quarter, topping the consensus estimate of $2.70 by $0.25. The firm had revenue of $3.38 billion for the quarter, compared to analysts’ expectations of $3.36 billion. DaVita had a net margin of 6.35% and a return on equity of 369.39%. The business’s quarterly revenue was up 6.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.00 earnings per share. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. As a group, analysts anticipate that DaVita will post 10.76 earnings per share for the current year.

Insider Transactions at DaVita

In related news, insider James O. Hearty sold 2,351 shares of the stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $150.00, for a total value of $352,650.00. Following the completion of the transaction, the insider directly owned 26,038 shares of the company’s stock, valued at $3,905,700. This represents a 8.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 1.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On DaVita

A number of institutional investors and hedge funds have recently made changes to their positions in DVA. UMB Bank n.a. increased its stake in shares of DaVita by 65.5% during the first quarter. UMB Bank n.a. now owns 192 shares of the company’s stock valued at $29,000 after purchasing an additional 76 shares in the last quarter. Copia Wealth Management bought a new stake in shares of DaVita during the fourth quarter valued at approximately $30,000. National Pension Service increased its position in shares of DaVita by 74.3% during the first quarter. National Pension Service now owns 197 shares of the company’s stock valued at $30,000 after acquiring an additional 84 shares in the last quarter. Hantz Financial Services Inc. increased its position in shares of DaVita by 48.1% during the second quarter. Hantz Financial Services Inc. now owns 231 shares of the company’s stock valued at $33,000 after acquiring an additional 75 shares in the last quarter. Finally, Y.D. More Investments Ltd bought a new stake in shares of DaVita during the first quarter valued at approximately $35,000. Institutional investors own 90.12% of the company’s stock.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.